DICERNA PHARMACEUTICALS INC's ticker is DRNA and the CUSIP is 253031108. A total of 1 filers reported holding DICERNA PHARMACEUTICALS INC in Q4 2021. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2021 | $3,046,000 | -47.1% | 151,085 | -2.1% | 0.01% | -45.5% |
| Q2 2021 | $5,761,000 | +19.7% | 154,359 | -18.0% | 0.01% | +10.0% |
| Q1 2021 | $4,814,000 | +1.9% | 188,254 | -12.2% | 0.01% | 0.0% |
| Q4 2020 | $4,723,000 | -0.8% | 214,393 | -19.0% | 0.01% | -9.1% |
| Q3 2020 | $4,761,000 | -14.1% | 264,610 | +21.3% | 0.01% | -15.4% |
| Q2 2020 | $5,540,000 | +29.6% | 218,074 | -6.3% | 0.01% | +18.2% |
| Q1 2020 | $4,274,000 | -10.1% | 232,710 | +7.8% | 0.01% | +10.0% |
| Q4 2019 | $4,756,000 | +1386.2% | 215,944 | +870.0% | 0.01% | +900.0% |
| Q3 2019 | $320,000 | -8.8% | 22,263 | 0.0% | 0.00% | 0.0% |
| Q2 2019 | $351,000 | +7.7% | 22,263 | 0.0% | 0.00% | 0.0% |
| Q1 2019 | $326,000 | +37.0% | 22,263 | 0.0% | 0.00% | 0.0% |
| Q4 2018 | $238,000 | -11.9% | 22,263 | +25.7% | 0.00% | 0.0% |
| Q3 2018 | $270,000 | +29.8% | 17,709 | +4.3% | 0.00% | – |
| Q2 2018 | $208,000 | – | 16,987 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aquilo Capital Management, LLC | 2,456,595 | $49,525,000 | 9.00% |
| COMMODORE CAPITAL LP | 1,292,251 | $26,052,000 | 6.87% |
| Bain Capital Life Sciences Investors, LLC | 3,080,237 | $62,098,000 | 3.85% |
| GREAT POINT PARTNERS LLC | 799,999 | $16,128,000 | 3.76% |
| DAFNA Capital Management LLC | 587,456 | $11,843,000 | 3.14% |
| Eagle Health Investments LP | 406,525 | $8,196,000 | 2.60% |
| RTW INVESTMENTS, LP | 7,582,396 | $152,861,000 | 2.30% |
| Parkman Healthcare Partners LLC | 209,686 | $4,227,000 | 1.07% |
| Palo Alto Investors LP | 855,713 | $17,251,000 | 1.04% |
| Lombard Odier Asset Management (Switzerland) SA | 701,305 | $14,138,000 | 0.88% |